Gene editing's next chapter will be focused on tackling cancers and more common diseases, uncovering new details about aging and other fundamental aspects of biology and editing RNA, top scientists in the field said this week.
The big picture: The potential of CRISPR gene-editing technology was realized six months ago, when the Food and Drug Administration approved the first therapy that uses the system to treat sickle-cell anemia. Now, scientists are setting their sights on more complex molecular targets.
